Systemic Overexpression of Angiopoietin-2 Promotes Tumor Microvessel Regression and Inhibits Angiogenesis and Tumor Growth
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Angiopoietin-2 (Ang-2) is a conditional antagonist and agonist for the endothelium-specific Tie-2 receptor. Although endogenous Ang-2 cooperates with vascular endothelial growth factor (VEGF) to protect tumor endothelial cells, the effect on tumor vasculature of high levels of exogenous Ang-2 with different levels of VEGF has not been studied in detail. Here, we report that systemic overexpression of Ang-2 leads to unexpected massive tumor vessel regression within 24 h, even without concomitant inhibition of VEGF. By impairing pericyte coverage of the tumor vasculature, Ang-2 destabilizes the tumor vascular bed while improving perfusion in surviving tumor vessels. Ang-2 overexpression transiently exacerbates tumor hypoxia without affecting ATP levels. Although sustained systemic Ang-2 overexpression does not affect tumor hypoxia and proliferation, it significantly inhibits tumor angiogenesis, promotes tumor apoptosis, and suppresses tumor growth. The similar antitumoral, antiangiogenic efficacy of systemic overexpression of Ang-2, soluble VEGF receptor-1, and the combination of both suggests that concomitant VEGF inhibition is not required for Ang-2–induced tumor vessel regression and growth delay. This study shows the important roles of Ang-2–induced pericyte dropout during tumor vessel regression. It also reveals that elevated Ang-2 levels have profound pleiotropic effects on tumor vessel structure, perfusion, oxygenation, and apoptosis. [Cancer Res 2007;67(8):3835–44]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 2×
“Vascular normalization is theorized to correct chaotic tumor blood flow, improve perfusion, and enhance tumor accessibility to antitumor drugs and oxygen (31).”
BackgroundHypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177 · cited 1×
“Tumor hypoxia not only up-regulates both VEGF and Ang-2 to promote angiogenesis in a concerted way, but also results in resistance to chemotherapy and radiotherapy by activating multiple survival signaling pathways (33, 34).”
BackgroundExploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828 · cited 1×
“Tumor hypoxia not only up-regulates both VEGF and Ang-2 to promote angiogenesis in a concerted way, but also results in resistance to chemotherapy and radiotherapy by activating multiple survival signaling pathways (33, 34).”
BackgroundHypoxia signalling in cancer and approaches to enforce tumour regression
Pouysségur, J., Dayan, F., & Mazure, N. M. (2006) · Nature · doi:10.1038/nature04871 · Cited by 1,676 · cited 2×
“The angiopoietin/Tie-2 family plays an important role in regulating vessel stability (4).”
BackgroundKinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170
Lobov, I. B., Brooks, P. C., & Lang, R. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172161899 · Cited by 676 · cited 2×
“(17) showed that VEGF converts Ang-2 from an antiangiogenic to a proangiogenic stimulus.”
BackgroundPleiotropic effects of HIF-1 blockade on tumor radiosensitivity
Moeller, B. J., Dreher, M. R., Rabbani, Z. N., Schroeder, T., Cao, Y., Li, C. Y., & Dewhirst, M. W. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.016 · Cited by 374
Self-citationCao, Y., Li, C.-Y., Moeller, B. J., Yu, D., Zhao, Y., Dreher, M. R., Shan, S., & Dewhirst, M. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4553 · Cited by 92
Self-citation
Cited by
Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system
Augustin, H. G., Young Koh, G., Thurston, G., & Alitalo, K. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2639 · Cited by 1,465
Fagiani, E., & Christofori, G. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.08.018 · Cited by 676
Resistance to targeted therapy in renal-cell carcinoma
Rini, B. I., & Atkins, M. B. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70240-2 · Cited by 569
VEGF and angiopoietin signaling in tumor angiogenesis and metastasis
Saharinen, P., Eklund, L., Pulkki, K., Bono, P., & Alitalo, K. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.01.015 · Cited by 478
Targeting the ANGPT–TIE2 pathway in malignancy
Huang, H., Bhat, A., Woodnutt, G., & Lappe, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2894 · Cited by 468
Metadata
- Authors
- Cao, Y., Sonveaux, P., Liu, S., Zhao, Y., Mi, J., Clary, B. M., Li, C.-Y., Kontos, C. D., & Dewhirst, M. W.
- Venue
- Cancer Research
- Published
- 2007-04-15
- Volume
- 67
- Issue
- 8
- Pages
- 3835-3844
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2079410628
- Cited by
- 99
- References
- 8
- FWCI
- 2.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systemic Overexpression of Angiopoietin-2 Promotes Tumor Microvessel Regression and Inhibits Angiogenesis and Tumor Growth. https://app.cochat.ai/papers/10.1158/0008-5472.can-06-4056
- The paper
- Cao, Y., Sonveaux, P., Liu, S., Zhao, Y., Mi, J., Clary, B. M., Li, C.-Y., Kontos, C. D., & Dewhirst, M. W. (2007). Systemic Overexpression of Angiopoietin-2 Promotes Tumor Microvessel Regression and Inhibits Angiogenesis and Tumor Growth. Cancer Research. https://doi.org/10.1158/0008-5472.can-06-4056
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.